Elon Musk’s SpaceX Acquires xAI in Historic Deal Uniting Space and Artificial Intelligence 
Novo Nordisk Warns of Profit Decline as Wegovy Faces U.S. Price Pressure and Rising Competition 
Tesla Launches New Model Y Variant in the US Starting at $41,990 
AMD Shares Slide Despite Earnings Beat as Cautious Revenue Outlook Weighs on Stock 
Boeing Signals Progress on Delayed 777X Program With Planned April First Flight 
Nvidia Nears $20 Billion OpenAI Investment as AI Funding Race Intensifies 
Hyundai Motor Lets Russia Plant Buyback Option Expire Amid Ongoing Ukraine War 
Nintendo Shares Slide After Earnings Miss Raises Switch 2 Margin Concerns 
Denso Cuts Profit Forecast Amid U.S. Tariffs and Rising Costs 
SpaceX Updates Starlink Privacy Policy to Allow AI Training as xAI Merger Talks and IPO Loom 
CK Hutchison Unit Launches Arbitration Against Panama Over Port Concessions Ruling 
Google Cloud and Liberty Global Forge Strategic AI Partnership to Transform European Telecom Services 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
SpaceX Reports $8 Billion Profit as IPO Plans and Starlink Growth Fuel Valuation Buzz 
Sam Altman Reaffirms OpenAI’s Long-Term Commitment to NVIDIA Amid Chip Report 
| Press Release Montrouge, France, June 1, 2017 |
DBV Technologies to Attend Upcoming Investor Conferences
DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) today announced that members of its management team will present and host investor meetings at the following investor conferences in June 2017:
Charles Ruban, Chief Commercial Officer, and Susanna Mesa, SVP, Strategy, will present at the Jefferies 2017 Global Healthcare Conference in New York, NY, on Wednesday, June 7, 2017, at 2:30pm ET.
Susanna Mesa, SVP, Strategy, will present at the Goldman Sachs 38th Annual Global Healthcare Conference in Rancho Palos Verdes, CA, on Tuesday, June 13, 2017, at 11:20am PT.
A live webcast of the Jefferies 2017 Global Healthcare Conference will be available on the Investor Relations section of the Company's website: http://www.dbv-technologies.com/en/investor-relations. A replay of the presentation will also be available on DBV's website within one hour after the event.
About DBV Technologies
DBV Technologies is developing Viaskin®, a proprietary technology platform with broad potential applications in immunotherapy. Viaskin is based on epicutaneous immunotherapy, or EPIT®, DBV's method of delivering biologically active compounds to the immune system through intact skin. With this new class of self-administered and non-invasive product candidates, the company is dedicated to safely transforming the care of food allergic patients, for whom there are no approved treatments. DBV's food allergies programs include ongoing clinical trials of Viaskin Peanut and Viaskin Milk, and preclinical development of Viaskin Egg. DBV is also pursuing a human proof-of-concept clinical study of Viaskin Milk for the treatment of Eosinophilic Esophagitis, and exploring potential applications of its platform in vaccines and other immune diseases.
DBV Technologies has global headquarters in Montrouge, France and New York, NY. Company shares are traded on segment A of Euronext Paris (Ticker: DBV, ISIN code: FR0010417345), part of the SBF120 index, and traded on the Nasdaq Global Select Market in the form of American Depositary Shares (each representing one-half of one ordinary share) (Ticker: DBVT). For more information on DBV Technologies, please visit our website: www.dbv-technologies.com
DBV Technologies Contact
Sara Blum Sherman
Director, Investor Relations
+1 212-271-0740
[email protected]
Media Contact
Andrea Fassacesia, Weber Shandwick
+1 212-445-8144
[email protected]
Media Contact Europe
Caroline Carmagnol, Alize RP, Relations Presse
+33 (0)6 64 18 99 59
[email protected]
Attachments:
http://www.globenewswire.com/NewsRoom/AttachmentNg/45911b99-72fe-44d1-a90a-f9336e13b87d
